Veri Medtech Holdings, Inc. has filed paperwork to uplist its common stock to the NASDAQ Capital Market, the company said in a statement. Alongside the listing application, the Delaware-based medical technology company has launched a firm commitment public offering to sell up to 3.75 million shares at a price of $4.00 per share.
If the offering is fully subscribed, the sale would generate up to $15 million in gross proceeds. The company currently distributes its common stock on the OTCID Market using the ticker symbol "VRHI." Veri Medtech reported a last trade price of $1.00 per share at market close on June 2, 2026.
Veri Medtech said it intends to maintain the "VRHI" ticker symbol if the NASDAQ approves the listing. The company also indicated that the public offering is contingent on NASDAQ granting the listing request - it stated it will not proceed with the offering if NASDAQ rejects the application.
In its filing, Veri Medtech highlighted that trading in its common stock is currently limited. The company noted that quotations on the over-the-counter market reflect inter-dealer prices without retail adjustments, and therefore those quotations may not accurately represent actual transaction volumes or the prices at which retail investors transact.
The filing combines the administrative step of seeking a national exchange listing with a financing transaction. The plan to keep the same ticker symbol on NASDAQ, if accepted, signals an intent to preserve continuity in the company’s market identity. The offering’s consummation, however, is explicitly tied to the outcome of the NASDAQ application, so the company will not move forward with the public sale absent exchange approval.
Clear summary
Veri Medtech has filed to uplist to NASDAQ while proposing a firm commitment sale of up to 3.75 million shares at $4.00 each, which would raise up to $15 million if fully subscribed. The company's stock currently trades on the OTCID Market under the VRHI symbol and last closed at $1.00 per share on June 2, 2026. The offering will not proceed if NASDAQ denies the listing application.
Key points
- Veri Medtech filed to list on the NASDAQ Capital Market and proposed a firm-commitment public offering of up to 3.75 million shares at $4 per share - potential proceeds up to $15 million.
- The company currently trades on the OTCID Market under the ticker VRHI, with a last reported closing price of $1.00 per share on June 2, 2026.
- The offering is conditional on NASDAQ approval, and Veri Medtech has said it will not proceed with the public sale if the exchange rejects its application - the company intends to retain the VRHI ticker on NASDAQ if listed.
Sectors affected: Healthcare equipment and supplies, capital markets.
Risks and uncertainties
- NASDAQ approval uncertainty - the company will not proceed with the offering if the exchange does not grant listing approval, which directly affects whether the financing transaction occurs - impact on capital markets and the company’s funding prospects.
- Limited public trading - Veri Medtech acknowledged constrained trading liquidity in its common stock, which may affect price discovery and transaction execution for investors - relevant to retail and institutional trading in OTC-listed securities.
- OTC quotation limitations - over-the-counter market prices represent inter-dealer quotations without retail adjustments and may not reflect actual transaction volumes, introducing uncertainty about the representativeness of reported OTC prices.
Note: The article reflects the company’s statements and filings. It does not add or infer outcomes beyond the information provided by the company.